Oster Howard S, Van de Loosdrecht Arjan A, Mittelman Moshe
Department of Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv University School of Medicine.
Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam.
Haematologica. 2025 Feb 1;110(2):300-311. doi: 10.3324/haematol.2023.284937.
The myelodysplastic syndromes (MDS) are a heterogenous group of clonal bone marrow (BM) stem cell myeloid neoplasms, characterized by BM dysplasia, macrocytic anemia or cytopenia with a tendency for leukemic transformation. The suspicion of MDS is raised by a typical but not specific clinical picture and routine laboratory findings, but the gold standard for the diagnosis of MDS is still BM examination with the presence of uni-or multi-lineage dysplasia and blast percentage, together with exclusion of other reasons. Cytogenetics is also a part of the diagnostic process. Flow cytometry and genetics are helpful but are not always mandatory for the diagnosis of MDS. This review summarizes the current steps in the diagnostic approach for a patient suspected of having MDS. We also describe new concepts that use non-invasive diagnostic technologies, especially digital methods as well as peripheral blood genetics. The hope is that one day these will mature, be introduced into clinical practice, and perhaps in many cases even replace the invasive BM biopsy.
骨髓增生异常综合征(MDS)是一组异质性的克隆性骨髓(BM)干细胞髓系肿瘤,其特征为骨髓发育异常、大细胞贫血或血细胞减少,并具有白血病转化倾向。典型但非特异性的临床表现和常规实验室检查结果会引发对MDS的怀疑,但MDS诊断的金标准仍然是骨髓检查,检查需存在单系或多系发育异常以及原始细胞百分比,同时排除其他原因。细胞遗传学也是诊断过程的一部分。流式细胞术和遗传学检查对MDS诊断有帮助,但并非总是必需的。本综述总结了疑似MDS患者诊断方法的当前步骤。我们还描述了使用非侵入性诊断技术的新概念,特别是数字方法以及外周血遗传学。希望有一天这些技术能够成熟并引入临床实践,甚至在许多情况下取代侵入性的骨髓活检。